neta
DISCOVERY
FOUNDED IN JANUARY OF 2024 BY DR NATHAN JAMES BARNETT PHD
At NETA, we hold health promotion at the highest regard—placing the well-being of individuals affected by epilepsy at the forefront of everything we do. We are a global, volunteer-led initiative focused on transforming the landscape of rare and complex epileptic disorders, including Dravet Syndrome, Temporal Lobe Epilepsy, KBG Syndrome, and Abdominal Epilepsy.
With a foundation in cutting-edge transcriptomic research and bioinformatics, NETA bridges the gap between scientific innovation and community impact. Our team of researchers, clinicians, and advocates work collaboratively to improve early diagnosis, enable personalized treatment pathways, and promote education and awareness across borders.
We are committed to empowering families, supporting clinicians, and elevating the voices of those living with rare forms of epilepsy—through research, outreach, and a shared mission to foster a healthier, more informed future for all.
epilepsy research insights coupled with novel health promotion
Where are currently focusing our research on Dravet Syndrome and Abdominal epilepsy. Our researchers work tirelessly to get the answers that no one else can.
Dravet Syndrome is a severe childhood epilepsy primarily associated with mutations in the SCN1A gene. It is characterized by early-onset seizures, developmental delays, and several comorbid conditions. Zebrafish models, due to their genetic similarity to humans, are used to simulate DS phenotypes and study disease mechanisms. Advances in RNA sequencing are revealing potential therapeutic targets and pathways for precision medicine approaches.
Abdominal epilepsy is an underrecognized subtype that typically presents with paroxysmal abdominal pain, cyclical vomiting, and abdominal migraines, often leading to misdiagnosis. Diagnosis is challenging because initial non-invasive gastrointestinal investigations frequently miss the condition, while EEG and MRI play a crucial role. Although most patients respond well to antiepileptic drugs, delays in diagnosis can increase the risk of refractory epilepsy.
ACCESS TO THE LARGEST CURATED GENOMIC DATA BASE IN THE WORLD FOR EPILEPSY READY TO BE MINDED BY OUR VOLUNTEERS
